Doravirine (Pifeltro)

All References

• Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20:397-405.
  [PubMed Abstract]
• Anderson MS, Gilmartin J, Fan L, et al. No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration. Antivir Ther. 2019;24:443-50.
  [PubMed Abstract]
• Anderson MS, Khalilieh S, Yee KL, et al. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Clin Pharmacokinet. 2017;56:661-9.
  [PubMed Abstract]
• Asante-Appiah E, Lai J, Wan H, et al. Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates. Antimicrob Agents Chemother. 2021;65:e0121621.
  [PubMed Abstract]
• Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P. The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects. Clin Drug Investig. 2017;37:571-579.
  [PubMed Abstract]
• Blevins SR, Hester EK, Chastain DB, Cluck DB. Doravirine: A Return of the NNRTI Class? Ann Pharmacother. 2019;:1060028019869641.
  [PubMed Abstract]
• Boyle A, Moss CE, Marzolini C, Khoo S. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine. Clin Pharmacokinet. 2019;58:1553-65.
  [PubMed Abstract]
• Colombier MA, Molina JM. Doravirine: a review. Curr Opin HIV AIDS. 2018;13:308-314.
  [PubMed Abstract]
• Deeks ED. Doravirine: First Global Approval. Drugs. 2018;78:1643-1650.
  [PubMed Abstract]
• Feng M, Sachs NA, Xu M, et al. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. Antimicrob Agents Chemother. 2016;60:2241-7.
  [PubMed Abstract]
• Feng M, Wang D, Grobler JA, Hazuda DJ, Miller MD, Lai MT. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59:590-8.
  [PubMed Abstract]
• Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. Antivir Ther. 2019;24:425-35.
  [PubMed Abstract]
• Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J Int AIDS Soc. 2014;17:19532.
  [PubMed Abstract]
• Greaves W, Wan H, Yee KL, Kandala B, Vaddady P, Hwang C. Doravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate. Antimicrob Agents Chemother. 2019. pii: AAC.01298-19.
  [PubMed Abstract]
• Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81:463-72.
  [PubMed Abstract]
• Khalilieh S, Yee KL, Sanchez RI, et al. Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study. Antimicrob Agents Chemother. 2017;61:e01364-16.
  [PubMed Abstract]
• Khalilieh SG, Yee KL, Fan L, et al. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers. Clin Drug Investig. 2017;37:975-984.
  [PubMed Abstract]
• Khalilieh SG, Yee KL, Sanchez RI, et al. Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects. J Clin Pharmacol. 2018;58:1044-52.
  [PubMed Abstract]
• Martin EA, Lai MT, Ngo W, et al. Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development. J Acquir Immune Defic Syndr. 2020;85:635-42.
  [PubMed Abstract]
• Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5:e211-e220.
  [PubMed Abstract]
• Molina JM, Squires K, Sax PE, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020;7:e16-e26.
  [PubMed Abstract]
• Orkin C, Squires KE, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68:535-44.
  [PubMed Abstract]
• Sanchez RI, Fillgrove KL, Yee KL, et al. Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019;49:422-32.
  [PubMed Abstract]
• Schürmann D, Sobotha C, Gilmartin J, et al. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS. 2016;30:57-63.
  [PubMed Abstract]
• Smith SJ, Pauly GT, Akram A, et al. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants. J Acquir Immune Defic Syndr. 2016;72:485-91.
  [PubMed Abstract]
• Thompson M, Orkin C, Molina JM, et al. Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. Clin Infect Dis. 2020;70:1336-1343.
  [PubMed Abstract]
• Wilby KJ, Eissa NA. Clinical Pharmacokinetics and Drug Interactions of Doravirine. Eur J Drug Metab Pharmacokinet. 2018;43:637-44.
  [PubMed Abstract]
• Yee KL, Khalilieh SG, Sanchez RI, et al. The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects. Clin Drug Investig. 2017;37:659-67.
  [PubMed Abstract]
• Yee KL, Sanchez RI, Auger P, et al. Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects. Antimicrob Agents Chemother. 2017; 61:e01757-16.
  [PubMed Abstract]